Monday, October 10, 2011 | |
09:00 - 09:15 | Welcoming remarks and opening of the workshop L. van der Pol, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL |
1. Viral vaccine development for human and veterinary applications | |
Session chairs: |
|
09:15 - 10:00 | How to leverage novel technologies to improve the development and manufacturing processes, and overcome the complexities of new vaccines H. Pinton, Sanofi Pasteur, Marcy L'Étoile/F; R. Labatut, Sanofi Pasteur, Lyon/F |
10:00 - 10:45 | Vaccinating animals to protect human health; the development of a save and efficacious Rift Valley Fever Virus (RVFV) vaccine D. Goovaerts, J.T.M. Koumans MSD Animal Health, Boxmeer/NL |
10:45 - 11:15 | Coffee break |
11:15 - 11:45 | Flu cell culture vaccines: the Novartis experience H. Lübben, Novartis Vaccines & Diagnostics GmbH, Marburg/D; P. Dormitzer, Viral Vaccine Research, NVD Cambridge, MA/USA |
11:45 - 12:15 | Survey for the occurrence of infectious bronchitis virus strains in chickens and the quick development and licensing of a live attenuated vaccine against QX-like infectious bronchitis virus H.J. Geerligs, G.J. Boelm, C.A.M. Meinders, B.G.E. |
12:15 - 13:15 | Lunch |
2. Viral vaccine products and characterization | |
Session chairs: |
S. Kochanek, University Hospital Ulm/D |
13:15 - 14:00 | Virosomes as delivery system for antigens J. Graveland-Bikker, Crucell N.V., Leiden/NL |
14:00 - 14:45 | A "cool" way to produce alphavirus VLP vaccines S.W. Metz, F. Feenstra, C. Geertsema, J.M. Vlak, G.P. Pijlman, Wageningen University/NL |
14:45 - 15:15 | Coffee break |
15:15 - 15:45 |
Development of a vaccine candidate for human use based on Theravecty's lentiviral vector technology: phase I/II clinical trial by In vivo injection of a therapeutic vaccine ThVO1 against HIV/AIDS |
15:45 - 16:15 | Exploring novel approaches to produce virus-like particles F. Fernandes, J. Vidigal, H. Tomás, M.J.T. Carrondo, A.S. Coroadinha, A.P. Teixeira, P. Alves, IBET/ITQB-UNL, Oeiras/P |
16:15 - 16:45 | Product fingerprinting for comparability and stability studies C. J. Westdijk, G.-J. Willems, J.-P. Amorij, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL; A. Hawe, Leiden/Amsterdam Center for Drug Research (LACDR), University of Leiden/NL; G. Kersten, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL |
16:45 - 17:00 | Automated analysis of microbial and viral titration assays facilitates validation and GLP compliant, high throughput testing J. Hare, CTL Europe GmbH, Bonn/D; P. Lehmann, Cellular Technology Limited, Shaker Heights, OH/USA |
19:00 | Dinner at the "Fleming's" Hamburger Allee 47-53, 60486 Frankfurt am Main |
Tuesday, October 11, 2011 | |
3. Trends and challenges in USP & DSP | |
Session chairs: |
L. van der Pol, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL U. Reichl, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg/D |
09:15 - 10:00 | Building on the unique biological properties of embryonic stem cells for the industrial manufacture of vaccines M. Mehtali, Vivalis SA, Nantes/F |
10:00 - 10:45 | MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high tires R. van Wielink, Central Veterinary Institute of Wageningen |
10:45 - 11:00 | Cultivation of insect cells in fully synthetic media F. Messi, Cell Culture Technologies, Gravesano/CH; |
11:00 - 11:30 | Coffee break |
11:30 - 12:00 | Trypsin supports high-yield influenza vaccine production in MDCK cells by inhibition of the cellular pathogen defense T. Frensing, C. Seitz, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg/D; U. Reichl, University of Magdeburg/D |
12:00 - 12:30 |
CIM monolithic columns for the downstream processing and in-process control of large biomolecules production |
12:30 - 13:00 | Improvements on peste des petits ruminants vaccine stability during production and storage A.C. Silva, ITQB-UNL/IBET, Oeiras/P; M.J.T. Carrondo, IBET, Oeiras, Portugal; P.M. Marques, ITQB-UNL/IBET, Oeiras/P |
13:00 - 13:30 |
Wrap-up and closing remarks |